FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer

M. J. Baker, E. Gazi, M. D. Brown, J. H. Shanks, P. Gardner, N. W. Clarke

    Research output: Contribution to journalArticlepeer-review

    52 Downloads (Pure)

    Abstract

    Fourier transform infrared (FTIR) spectroscopy is a vibrational spectroscopic technique that uses infrared radiation to vibrate molecular bonds within the sample that absorbs it. As different samples contain different molecular bonds or different configurations of molecular bonds, FTIR allows us to obtain chemical information on molecules within the sample. Fourier transform infrared microspectroscopy in conjunction with a principal component- discriminant function analysis (PC-DFA) algorithm was applied to the grading of prostate cancer (CaP) tissue specimens. The PC-DFA algorithm is used alongside the established diagnostic measures of Gleason grading and the tumour/node/metastasis system. Principal component-discriminant function analysis improved the sensitivity and specificity of a three-band Gleason score criterion diagnosis previously reported by attaining an overall sensitivity of 92.3% and specificity of 99.4%. For the first time, we present the use of a two-band criterion showing an association of FTIR-based spectral characteristics with clinically aggressive behaviour in CaP manifest as local and/or distal spread. This paper shows the potential for the use of spectroscopic analysis for the evaluation of the biopotential of CaP in an accurate and reproducible manner. © 2008 Cancer Research.
    Original languageEnglish
    Pages (from-to)1859-1866
    Number of pages7
    JournalBritish Journal of Cancer
    Volume99
    Issue number11
    DOIs
    Publication statusPublished - 2 Dec 2008

    Keywords

    • FTIR microspectroscopy
    • Gleason grade
    • Infrared spectroscopy
    • Molecular diagnosis
    • PC-DFA
    • Prostate cancer

    Fingerprint

    Dive into the research topics of 'FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer'. Together they form a unique fingerprint.

    Cite this